These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27832868)

  • 21. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 23. Oseltamivir becomes plentiful--but still not cheap.
    Enserink M
    Science; 2006 Apr; 312(5772):382-3. PubMed ID: 16627733
    [No Abstract]   [Full Text] [Related]  

  • 24. Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
    Korr M
    R I Med J (2013); 2014 Jul; 97(7):29-30. PubMed ID: 24983018
    [No Abstract]   [Full Text] [Related]  

  • 25. [On the brink of a new era in the treatment of chronic hepatitis C virus infection in Denmark].
    Eiset AH; Holm MP; Leutscher PD
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Economic public health significance of generic drugs].
    Tschabitscher D; Waechter F; Müllner M
    Wien Klin Wochenschr; 2009; 121(11-12):365-71. PubMed ID: 19626293
    [No Abstract]   [Full Text] [Related]  

  • 27. Aerosolized ribavirin: the most expensive drug for pneumonia.
    Chemaly RF; Aitken SL; Wolfe CR; Jain R; Boeckh MJ
    Transpl Infect Dis; 2016 Aug; 18(4):634-6. PubMed ID: 27214684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A buyers' club to improve access to hepatitis C treatment for vulnerable populations.
    Vernaz N; Calmy A; Hurst S; Jackson Y; Negro F; Perrier A; Wolff H
    Swiss Med Wkly; 2018 Aug; 148():w14649. PubMed ID: 30141526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new hepatitis C virus bottleneck: Can delaying therapy be justified?
    Simon TG; Chung RT
    Hepatology; 2015 Sep; 62(3):666-7. PubMed ID: 26058922
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF; Reed SD; Muir AJ
    Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. It's time to end insurance restrictions on life-saving hepatitis C treatments.
    Clary R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
    [No Abstract]   [Full Text] [Related]  

  • 32. [Not Available].
    Stingl W
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048126
    [No Abstract]   [Full Text] [Related]  

  • 33. HIV/HCV Co-infection: Overcoming Barriers to Treatment.
    Gross C; Akoth E; Price A; Kattakuzhy S; Silk R; Rosenthal E
    J Assoc Nurses AIDS Care; 2016; 27(4):524-9. PubMed ID: 26996983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Price survey. Generic drug market heats up.
    Hosp Mater Manage; 2001 Mar; 26(3):1, 12-3. PubMed ID: 11975141
    [No Abstract]   [Full Text] [Related]  

  • 35. International prices and availability of pharmaceuticals in 2005.
    Danzon PM; Furukawa MF
    Health Aff (Millwood); 2008; 27(1):221-33. PubMed ID: 18180499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.
    Lim SG
    World J Gastroenterol; 2015 Feb; 21(6):1972-81. PubMed ID: 25684966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access to essential medications for HIV/AIDS in South Africa.
    Andrews S
    S Afr Med J; 2001 May; 91(5):384-7. PubMed ID: 11455797
    [No Abstract]   [Full Text] [Related]  

  • 39. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
    Reau NS; Jensen DM
    Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
    [No Abstract]   [Full Text] [Related]  

  • 40. Countries should encourage use of generic substitutes, says OECD.
    Zarocostas J
    BMJ; 2008 Oct; 337():a1996. PubMed ID: 18842656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.